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http://www.biomedcentral.com/1471-2369/15/172RESEARCH ARTICLE Open AccessThe incremental treatment of ESRD: a low-protein
diet combined with weekly hemodialysis may be
beneficial for selected patients
Stefania Caria1*, Adamasco Cupisti2, Giovanna Sau3 and Piergiorgio Bolasco1Abstract
Background: Infrequent dialysis, namely once-a-week session combined with very low-protein, low-phosphorus
diet supplemented with ketoacids was reported as a useful treatment schedule for ESRD patients with markedly
reduced residual renal function but preserved urine output. This study reports our findings from the application of
a weekly dialysis schedule plus less severe protein restriction (standard low-protein low-phosphorus diet) in stage 5
CKD patients with consistent dietary discipline.
Methods: This is a multicenter, prospective controlled study, including 68 incident CKD patients followed in a
pre-dialysis clinic with Glomerular Filtration Rate 5 to 10 ml/min/1.73/ m2 who became unstable on the only medical
treatment. They were offered to begin a Combined Diet Dialysis Program (CDDP) or a standard thrice-a-week
hemodialysis (THD): 38 patients joined the CDDP, whereas 30 patients chose THD. Patients were studied at baseline, 6
and 12 months; hospitalization and survival rate were followed-up for 24 months.
Results: Volume output and residual renal function were maintained in the CDDP Group while those features dropped
quickly in THD Group. Throughout the study, CDDP patients had a lower erythropoietin resistance index, lower β2
microglobulin levels and lower need for cinacalcet of phosphate binders than THD, and stable parameters of nutritional
status. At 24 month follow-up, 39.4% of patients were still on CDDP; survival rates were 94.7% and 86.8% for CDDP and
THD patients, respectively, but hospitalization rate was much higher in THD than in CDDP patients. The cost per patient
per year resulted significantly lower in CDDP than in THD Group.
Conclusions: This study shows that a CDDP served to protect the residual renal function, to maintain urine volume
output and to preserve a good nutritional status. CDDP also blunted the rapid β2 microglobulin increase and
resulted in better control of anemia and calcium-phosphate abnormalities. CDDP was also associated with a lower
hospitalization rate and reduced need of erythropoietin, as well as of drugs used for treatment of calcium-phosphate
abnormalities, thus leading to a significant cost-saving. We concluded that in selected ESRD patients with preserved
urine output attitude to protein restriction, CDDP may be a beneficial choice for an incremental hemodialysis program.
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The Epidemiology of chronic kidney disease (CKD) is on
an upward trend worldwide. Since the 1990s incidence
has risen by approximately 40% per decade, with preva-
lence rates in the general adult population up to 13% in
the USA and ranging 10.2-11.6% in Europe [1-4]. These
figures indicate a CKD epidemic leading to an increased* Correspondence: cariastefan@tiscali.it
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on public health resources.
Nutritional and pharmacological therapy constitute the
basis for the prevention and treatment of signs and symp-
toms of CKD, and they serve to delay the commencement
of dialysis. The appropriate time to start dialysis is still a
matter of debate. In particular, dialysis is not superior that
conservative treatment especially in the comorbid-elderly
population. It is known that a standard thrice–weekly
hemodialysis schedule invariably leads to rapid loss of thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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backs, and to high costs. Real incremental dialysis programs
are implemented in peritoneal dialysis but not in the
hemodialysis setting where only a twice -weekly schedule
may be proposed prior to maintenance hemodialysis.
During the 1980’s and 1990’s, an Integrated Diet Dialysis
Program (IDDP) was proposed as a therapeutic option for
selected patients with markedly reduced residual renal
function and it consisted of weekly hemodialysis session
(HD) combined with nutritional therapy, namely a very
low-protein diet supplemented with ketoacids [5-8]. Mal-
nutrition risk and low compliance to the severe dietary re-
strictions represented major concerns that prevented a
widespread application of this schedule. In the present
study we propose a Combined Diet Dialysis Program
(CDDP) which includes a less severe low protein (0.6
g/Kg/d) diet combined with once-weekly hemodialysis.
The goal is to prolong a conservative approach and
thus reduce the need for hemodialysis, thereby limiting
the risk of malnutrition and of poor dietary adherence.
This study aimed to assess the safety, benefits and
drawbacks of the CDDP approach including nutritional
status, residual renal function, morbidity, mortality
and costs.Table 1 Baseline characteristics of the studied groups
CDDP group
(n = 38)
THD group
(n = 30)
p
Male/females 25/13 19/11
Age, years 64.5 ± 13.2 65.2 ± 11 0.82
Body weight (kg) 65.5 ± 15.1 66.2 ± 11.9 0.73
BMI (kg/m2) 23.7 ± 4.0 25.6 ± 4.13 0.03
Urine volume output (mL/24 h) 1983 ± 651 1472.6 ± 433 <0.001
GFR (mL/min × 1.73 mq b.s) 7.8 ± 1.9 9.2 ± 4.2 <0.01
EPO (IU/kg/week) 104 ± 108 184 ± 84 <0.001
CRP <5 mg/dl, % 89 66.6 <0.01
iPTH, >300 ρg/mL, % 31.5 50 <0.01
Charlson comorbidity
index score
5.5 ± 2.5 3.8 ± 2.5 0.004
Charlson comorbidity
index score >4, %
62.5 33.3 <0.01Methods
This is a multicenter, non-randomized, prospective con-
trolled study, including stage V CKD patients followed
in a pre-dialysis clinic who were not suitable for a peri-
toneal dialysis program.
Patients with GFR 5 to 10 ml/min who were ap-
proaching hemodialysis treatment and who had vascular
access were included in the study. Global criteria of
starting dialysis and then for entering the study were
fluid retention, inadequate control of BUN or severe sec-
ondary hyperparathyroidism or hyperphosphatemia, re-
duced compliance to dietary treatment.
Patients with pericarditis, congestive heart failure, severe
fluid retention, overt protein-energy wasting, hyperkale-
mia or severe metabolic acidosis with acute reduction of
residual renal function or concurrent diseases were ex-
cluded, as well patients with unreliable discipline with
regards to dietary restrictions were treated at once with
maintenance hemodialysis and then excluded from the
study. During the pre-dialysis phase, patients were followed
in a tertiary care CKD clinic every two-three months (stage
4) or on a monthly basis (stage 5). Compliance to diet-
ary and pharmacological treatment was acceptable, as
assessed by urinary urea excretion and by dietary recall
and interview.
Sixty-eight incident patients were recruited and all the
patients were provided a functioning native artero-
venous fistula or graft.Underlying kidney diseases included mainly hyperten-
sion/vascular nephropathy, ADPKD. The patients were
offered the choice to commence a weekly hemodialysis
schedule plus low-protein diet on the non-dialysis day
(namely, CDDP), or to begin a standard thrice- weekly
hemodialysis (THD) schedule and free-choice diet. All the
patients were informed and directly involved in the deci-
sion making process. Randomization was not applied since
any dietary regimen requires adherence and motivation.
According to their own choice, 38 patients entered in
the CDDP Group, whereas the remaining 30 patients
formed the THD control group. The clinical and biochem-
ical features of the two groups at baseline are reported in
Table 1. At baseline, the prevalence of cardiovascular
disease history was similar in CDDP (28.9%) and in THD
(30%) group. Six type 2 diabetics were included in CDDP
group and 13 in THD group.
All the patients were studied at baseline, and after 6
and 12 months. The survival rate and hospitalization
rate were followed up to 24 months.
Blood samples were collected from the arterial line be-
fore the start of the first dialysis of the week; 24h urines
were collected during the day before the HD session.
GFR was measured as the average of creatinine clearance
and urea clearance, and expressed as ml/min*1.73 m2
body surface area [9]; eGFR was also estimated by MDRD
formula [10]. Protein catabolic rate (PCR) was used as an
indicator of dietary protein intake and calculated by the
urea appearance method according to Maroni’s formula
[11]. Maroni’s formula was used throughout the course of
the CDDP and only at baseline time in patients in the
THD Group. Within the THD Group, for patients with
the significant loss of renal function and urine output vol-
ume we included the method of urea kinetics model for
estimation of nPCR. Dialytic adequacy was expressed
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Body mass index was calculated by the body weight at
the end of the dialysis session. The bioelectrical parame-
ters, were measured with a single-frequency impedance
analyzer (BIA 101 – Akern - Florence), 30’ after the end
of the hemodialysis session.
Erythropoietin Resistance Index (ERI) was calcu-
lated as weekly EPO dosage (units)/body weight (Kg)/
Hb (g/dl) [13].
Charlson’s comorbidity index (CCI) score, was calcu-
lated to evaluate comorbidity conditions [14].
Creatinine production, as a surrogate of muscle mass,
was calculated by the sum of 24h urine creatinine excre-
tion and metabolized creatinine. Metabolized creatinine
was calculated from the product of serum creatinine
and extrarenal Creatinine clearance (estimated as 0.038
L/kg BW/d) [7].
All the patients on CDDP underwent nutritional coun-
seling by a renal dietician and were prescribed a low pro-
tein (0,6 g/kg b.w./d), low phosphorus (600–700 mg/d),
low sodium diet with an energy intake of 30–35 kcal/kg b.
w./d. Proteins were mostly from animal sources (0.4 g/Kg/
b.w.), to cover the requirement of essential amino acids;
no dairy or processed foods are included to the aim of lim-
iting the sodium and phosphorus intake; [15] protein-free
products are included to supply energy with negligible
load of phosphorus, sodium, potassium and nitrogen [16].
The 60–62% of energy intake derived from carbohydrates
(mostly represented by protein-free products), 30–32%
from lipids and 8-10% from proteins. As average, the daily
dietary plan consisted of 5–7 servings of protein free prod-
ucts, namely 2–3 serving for breakfast and snacks and 2
servings for both lunch and dinner; the patients were usu-
ally advised that they can add other servings, when required
to satisfy the energy requirement. The servings of animal
protein sources (meat, fish, egg white) were calculated for
each patient in order to guarantee a daily total amount of
0.4 g protein per kg b.w. Two servings of vegetables and
two of fruits were provided with specific suggestions for pa-
tients with high potassium levels as well as boiling was sug-
gested to reduce to mineral content (potassium, sodium,
calcium, and phosphorus) of food. Finally, 5–6 servings of
fats (olive oil as first choice) were suggested.
This diet was prescribed for 6 days a week, while no
dietary restrictions occurred on the dialysis day.
Patients in the THD control group followed an unre-
stricted protein diet, but they were given dietary coun-
seling focused on preventing excess sodium, potassium,
phosphorus and fluid intakes.
All the patients were prescribed 4-hour hemodialysis
sessions with highly biocompatible synthetic membranes.
The study protocol was approved by the Cagliari Hos-
pital Ethics Committee, and all the patients gave their
written informed consent for participation in the study.Statistical analysis
Descriptive statistics is given as mean ± standard deviation.
Normality tests were performed on all continuous vari-
ables measured throughout the study. The log-rank test
was used for hypothesis testing. Time repeated measure-
ments were analyzed using linear mixed models includ-
ing treatment, time, and treatment by time interaction
for all measured variables using ANOVA. Inter-group
drug use was compared by means of the binomial test
with Bonferroni’s correction for multiple comparisons.
Differences were considered as statistically significant
when p <0.05.
Results
Patients who entered the CDDP showed several differ-
ences with respect to patients who commenced THD
(Table 1). Despite a lower residual renal function (RRF),
CDDP patients showed lower circulating levels of phos-
phate, BUN, PTH and higher albumin levels with respect
to THD patients. 34 out of the 38 patients were still on
CDDP at 12 months: 2 patients were shifted to a thrice-
weekly dialysis schedule at 8 and 10 months, while 2 pa-
tients partially recovered their renal function and
remained clinically stable with the low-protein diet and
no need for dialysis.
During the study period, GFR was preserved in CDDP
patients in comparison to THD group (Table 2). GFR loss
progression was very low in the former (−0.13 ml/min/
month) while it was faster in the latter (−1.53 ml/min/
month). Similarly, in the CDDP group an effective urine
volume output was maintained whereas it dramatically
dropped in the THD patients (Figure 1a). As a conse-
quence, the interdialytic weight gain in CDDP patients
was limited to (800 ± 300 g) per week. The dosage of fru-
semide increased from 150 ± 154 to 273 ± 201 mg/day in
the CDDP group, and from 332 ± 171 to 409 ± 205 mg/
day (p =0.003) in the THD group. The increase of β2-
microglobulin circulating levels was much lower in CDDP
than in THD patients (+11.2% vs +34%, respectively)
(Figure 1c).
No difference in arterial blood pressure values
emerged between the two groups.
The main nutritional indicators, i.e. total protein, albu-
min and transferrin improved significantly in the CDDP
group (Figure 1b, Table 2). Estimated dietary protein in-
take remained stable in the CDDP groups throughout the
study (from 0.58 ± 0.2 to 0.57 ± 0.11 g/kg/day). This was
also the case for THD patients (from 1.03 ± 0.1 to 1.04 ±
0.3 g/kg/day). No significative changes in body weight or
Body Mass Index (BMI) were recorded in the two groups
(Table 2).
A significant reduction in the ESAs requirement was
observed in the CDDP group along with markedly lower
ERI values (Table 3).
Table 2 Outcome of nutritional and functional parameters in both groups in 12 months
CDDP group THD group
Baseline
(n = 38)
6 months
(n = 38)
12 months
(n = 34)
Baseline
(n = 30)
6 months
(n = 30)
12 months
(n = 29)
P
Dry weight (kg) 65 ± 15.0 63.9 ± 14.4 63.4 ± 14.7 66.2 ± 11.9 64.9 ± 11.5 65.5 ± 12.3 0.07
BMI (kg/m2) 23.7 ± 4.0 23.4 ± 3.7 23.0 ± 3.9 25.6 ± 4.13 25.1 ± 4.07 25.4 ± 4.2 0.07
Total body water (L) 44.4 ± 10.5 41 ± 9.6 43 ± 11 35.4 ± 6 33.5 ± 5.8a 33.8 ± 5.9a 0.02
Extracellular water (L) 20 ± 4.5 18.6 ± 4.3 19.7 ± 4 17.5 ± 3.2 16 ± 2.8b 15.7 ± 2.4b 0.04
Fat mass (kg) 11 ± 12.3 13 ± 11.8 11.4 ± 11 20 ± 9 21.4 ± 8.5 22.6 ± 9.4 0.03
Body cell mass (kg) 31 ± 9.6 28 ± 8.9 29.7 ± 10.3 22.5 ± 6.2 22.7 ± 5 22.7 ± 5.8 0.02
Phase angle, (°) 6.2 ± 1.3 6.2 ± 1.3 6.1 ± 1.4 5.0 ± 1.2 6 ± 0.9 5.8 ± 1.2 0.06
SBP (mmHg) 139 ± 18 132 ± 20 128 ± 15b 136.8 ± 17.2 138.5 ± 18.5 139 ± 20.8 0.21
DBP (mmHg) 80 ± 12 73 ± 10 74 ± 9c 71.6 ± 11.4 71.6 ± 10 72.9 ± 12.3 0.08
Serum creatinine (mg/dL) 6.4 ± 1.9 7.0 ± 2.5 7.8 ± 3.0b 5.9 ± 1.8 7.8 ± 2.2 8.2 ± 2.4b 0.05
B.U.N. (mg/dL) 68 ± 18 68 ± 16 70 ± 17 84.4 ± 18.5 77 ± 15.5 77 ± 22.9 0.003
GFR (mL/min) 7.8 ± 1.9 6.7 ± 2.3 6.3 ± 2.1b 9.2 ± 4.2 - - -
eGFR (mL/min) 9.4 ± 2.9 8.4 ± 3.5a 8.0 ± 3.4b 10.3 ± 3.9 - - -
Total protein (g/dL) 6.7 ± 0.5 6.7 ± 0.5 6.8 ± 0.4 6.35 ± 0.52 6.4 ± 0.5 6.5 ± 0.43 0.004
Albumin (g/dL) 3.8 ± 0.4 3.9 ± 0.4 4.1 ± 0.4b 3.6 ± 0.40 3.6 ± 0.37 3.7 ± 0.48 0.01
Transferrine (mg/dL) 219 ± 53 203 ± 72 222 ± 53 264 ± 94 249 ± 43 251 ± 61 0.001
C3 (mg/dL) 90 ± 20 91 ± 23 94 ± 23 99.6 ± 39.6 96 ± 35.7 95.9 ± 32 0.48
C4 (mg/dL) 24 ± 7 24 ± 8 26 ± 7 33 ± 28 29 ± 18 29 ± 30 0.26
Total IgG (mg/dL) 1599 ± 497 1590 ± 402 1543 ± 373 1440 ± 461 1482 ± 487 1409 ± 413 0.21
Lynphocytes/mm3 1539 ± 651 1390 ± 831 1581 ± 537 1452 ± 811 1458 ± 622 1445 ± 580 0.38
Legend: changes versus baseline: ap < 0.05; bp < 0.01; c< 0.03; P: ANOVA significance for treatment by time interaction.
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stable and better controlled in the CDDP (Table 3,
Figure 1d) group despite a significantly lower use of
non-calcium containing phosphate-binders and cinacal-
cet and among all the drugs, only allopurinol use was
reduced during THD (Table 4).
Calcimimetics drugs are not delivered by Italian NHS
during the pre-dialysis phase.
So their use began after commencing dialysis (even
once-a-week): patients on THD showed a secondary
hyperparathyroidism more severe than patients on CDDP ,
consequently the need of calcimimetics was higher in the
former than in the latter.
No significant reduction in creatinine production was
observed after 12 months of CDDP (16.8 ± 4.3 vs. 15.9 ±
3.9 mg/Kg/d).
Hospitalization
Throughout the 24 month follow-up period, 3 CDDP
patients were admitted to hospital for a total of 11 days
(3.7 ± 1.5 days/patient) due to atrial fibrillation, acute
bronchitis and acute cholecystitis. Instead 24 hospital
admission were recorded in 15 patients of THD groups
for a total of 147 days (6.1 ± 6.3 days/patient). Causes for
admission were: set up of new vascular access (7), artero-venous fistula stenosis angioplasty (1), infection of central
vein catheter (2), acute pulmonary edema (1), surgery for
biological prosthetic valve (1), myocardial infarction (1),
valvular and coronaropathy angioplasty (2), congestive
heart failure (1), atrial fibrillation (2), hyperpyrexia (1),
hypertensive crisis (1), hypoglycemic coma (1), abscess in
thigh hematoma (1) and obstructive jaundice secondary to
gallstones (2).
Survival
At the 24-month follow-up, no significant difference was
detected between the CDDP and THD group survival
rates: 94.7% and 86.8% respectively (Figure 2).
Death in 3 CDDP patients was caused by cardiac events:
1 during the 13th, 1 during the 16th and 1 during the 18th
month of CDDP. Four deaths occurred in the THD group:
1 in the 9th, 2 in the 13th and 1 in the 22nd month follow-
ing start of dialysis. Causes included myocardial infarction
and acute heart failure, sepsis and stroke.
CDDP global outcome
At 12 months 34 out of the 38 patients (89.5%) were on
CDDP. At 24 months, 15 patients were still on CDDP
(39.4%) since 1 patient received a kidney transplant, 3 pa-
tients had fatal myocardial infarction, whereas 17 patients
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Figure 1 Changes in urine volume (a), serum albumin (b), β2-microglobulin (c) and serum phosphorus (d) in CDDP Group (dotted Line)
and THD Group (full line), at baseline, 6 and 12 months of follow-up.
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(namely twice to thrice-weekly dialysis and free-protein
diet) and 2 patients partially recovered their renal func-
tion. The main reasons for dropping out were loss of diet-
ary adherence and/or reduction of residual renal function.
When compared to THD group, CDDP patients regis-
tered a lower number of hospitalizations and a lower
need for expensive drugs. These findings, coupled with
the 66% reduction in number of dialysis sessions (52 ver-
sus 156 sessions in THD Group in a year) allows to esti-
mated that the cost of a CDDP patient is more than 60%
less than that of a THD patient.
Discussion
This study shows that in selected ESRD patients, a
CDDP is able to protect the RRF, to maintain urine vol-
ume output, to preserve a good nutritional status, to
blunt the rapid β2 microglobulin increase, and to allow
better control of anemia and calcium-phosphate abnor-
malities. CDDP is also associated with a lower rate of
hospitalization , reduced need of EPO and drugs used
for the CKD-MBD treatment, thus leading to a signifi-
cant cost-saving. CCDP may be considered as the first
step of an incremental approach to hemodialysis treat-
ment of ESRD.
Patients who entered the CDDP showed a better con-
trol of phosphatemia, BUN, PTH levels and higheralbumin levels despite a lower RRF. It suggests that pa-
tients who had maintained consistent adherence to dietary
treatment chose the CDDP whereas THD was chosen by
patients with poor compliance to dietary prescriptions. In
fact, dietary discipline is the first pre-requisite for a safe
and successful CDDP.
In the CDDP group an effective urine volume output
was maintained whereas it dramatically dropped in the
THD patients. As a consequence, the interdialytic weight
gain in CDDP patients was quite small, thus allowing low
intradialytic ultrafiltration volumes. In turn, this may con-
tribute to further preservation of the residual renal func-
tion and to limit cardiovascular damage. When compared
to THD, CDDP was not associated with greater mortality
risk (Figure 2) and hospitalization rate was much lower.
One of the main goals of the CKD patients care is to
preserve RRF as long as possible because it is of very fa-
vorable prognostic value. The majority of patients suc-
ceeded in sticking to CDDP for at least one year ensuring
a good nutritional status and maintaining GFR (−1.56 ml/
min/year); in stage 4–5 CKD Levin et al. reported a GFR
loss of 2.6 ml/min/year [17].
Three major studies investigated once a-weekly dialysis
coupled with low protein regimens in ESRD patients
[5-8]. Mitch et al. reported that combined diet-dialysis
treatment resulted in a decrease in urea production with
a positive nitrogen balance during interdialytic interval
Table 3 Biochemistry parameters in CDDP and THD groups at 6 and 12 months
CDDP group THD group
Baseline
(n = 38)
6 months
(n = 38)
12 months
(n = 34)
Baseline
(n = 30)
6 months
(n = 30)
12 months
(n = 29)
P
Triglycerides (mg/dL) 109 ± 36 134 ± 92 126 ± 50 131 ± 72 152 ± 67 139 ± 52 0.03
Total Cholesterol (mg/dL) 164 ± 36 168 ± 36 164 ± 35 165 ± 41 168.5 ± 34 170 ± 40 0.51
HDL Cholesterol (mg/dL) 44 ± 14 47 ± 13 48 ± 20 44 ± 12 45 ± 13 44 ± 12 0.58
LDL Cholesterol (mg/dL) 101 ± 29 93 ± 34 93 ± 31 95 ± 32 93 ± 29 97.8 ± 34 0.95
Cholinesterases (UI/mL) 5474 ± 1396 6073 ± 1474 586 ± 1646 4968 ± 1488 5511 ± 1604 4673 ± 1450b 0.27
Uric acid (mg/dL) 7.3 ± 2.3 7.5 ± 2.4 7.1 ± 1.9 6.4 ± 1.8b 7.3 ± 1.2 7.2 ± 1.3b 0.60
Sodium (mmol/L) 139 ± 2.6 137 ± 3.6 137 ± 4.0 138 ± 2.7 138 ± 2.3 134 ± 3.3 0.58
Potassium (mmol/L) 4.4 ± 0.6 4.3 ± 0.6 4.3 ± 0.7 4.3 ± 0,67 4.7 ± 0.7 4.8 ± 0.9b 0.07
Calcium (mg/dL) 9.2 ± 0.5 9.0 ± 0.5 9.1 ± 0.6 9.1 ± 0.6 9.1 ± 0.7 9.0 ± 0.5 0.51
Phosphatemia (mg/dL) 4.4 ± 0.9 4.6 ± 0.8 4.6 ± 0.8 5.1 ± 1.5 5.6 ± 1.1 5.2 ± 1.1 0.001
Bicarbonate (mEq/L) 22.0 ± 3.1 23.1 ± 3.3 23.2 ± 3.2 21.8 ± 4.2 21.9 ± 3.2 21.6 ± 2.7 0.17
β2-microglobulin (mg/dL) 14.2 ± 3.9 16.8 ± 5.7 16.0 ± 5.1 18.4 ± 11.6 31.0 ± 16.0 28.0 ± 11.4b 0.007
Hb (g/dl) 10.8 ± 0.1 11.5 ± 0.95 11.5 ± 0.97a 10.5 ± 1.4 11.3 ± 0.9 11.2 ± 0.95a 0.31
EPO (IU/kg/week) 104 ± 108 69 ± 59 60 ± 74b 184 ± 84 172 ± 138 204 ± 252 0.002
ERI (IU/kg/week)/Hb 10 ± 11 6 ± 5 5 ± 7b 19 ± 10 15 ± 13 19 ± 23 <0.001
CRP (% patients) <5.0 89 81.5 79 66.6 83.3 76.6 <0.05
CRP (mg/dL) 3.3 ± 3.9 3.5 ± 3.3 3.2 ± 3.6 8.6 ± 9.7 4.9 ± 6.5 5.8 ± 5.8 <0.01
iPTH (ρg/mL) <150 (%) 39.5 52.6 52 36.7 43.3 34.5 0.09
iPTH (ρg/mL) 150–300 (%) 29 29 30 13.3 20 27.6 0.26
iPTH (ρg/mL) >300 (%) 31.5a 18.4 18a 50 36.7 37.9 0.02
Changes versus baseline: ap < 0.01; bp < 0.03; P: ANOVA significance for treatment by time interaction.
Table 4 Pharmacologic treatments in CDDP and THD groups
CDDP Group THD group P
% of patients Baseline 12months Baseline
12
months
ACEi 34 33 50 48.3 n.s
ARBs 24 26 30 21 n.s
Calcium channel blockers 28.9 27.3 30 17 n.s
Calcium carbonate 59 60 76.6 72.4 n.s.
Sevelamer or
Lanthanum
carbonate
0 12a 0 41c <0.03
Paricalcitol 0 12b 0 17.2b n.s.
Cinacalcet 0 6b 0 24c <0.04
Calcitriol 45 42 46.7 45 n.s.
Kayexalate 21 21 20 38 n.s.
Allopurinol 48.6 54 33.3 13.8a 0.01
Statins 37 33 26.7 24 n.s
Polyunsaturated fats 13 9 10 17 n.s.
Legend: Changes versus baseline: ap<0.05; bp<0.01; c<0.03; P: ANOVA
significance for treatment by time interaction.
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uremic symptoms even after years of IDDP despite an
extremely low RRF, thus indicating that the nutritional
therapy is a major factor preventing the onset of uremic
symptoms [6]. The studies carried out by Locatelli et al.
concluded that IDDP may be very important from a psy-
chological and economic point of view, but concerns
arose about compliance and long-term nutritional and
depurative adequacy [7]. After a 4-year period they
found a reduction of creatinine generation rate, possibly
suggesting a reduction in muscle mass.
This was not confirmed in our patients where the CDDP
differs from the similar strategies proposed in the 1980’s and
1990’s [6,7]; the treatment is distinguished by less severe
residual renal function from among patients, less severe
protein restriction, and by closer nutritional monitoring. In
addition, hemodialysis sessions were performed with high
quality water and highly bio-compatible membranes [18-21].
Retrospective and prospective studies failed to dem-
onstrate any benefits, in terms of survival, for an early
onset of dialysis. In 2010 the first randomized, con-
trolled trial of early versus late initiation of dialysis re-
ported that early access to dialysis (eGFR > 7 ml/min/
1.73 m2) provided no statistically significant benefits in
terms of patient survival [22].
Figure 2 Cumulative survival in CDDP group (Dotted line) and
in THD Group (Full line).
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sized molecules such as β2-microglobulin is well-
known (Figure 1c). Accordingly, patients with a significant
RRF manifest lower levels of β2-microglobulin. On com-
mencing CDDP, maintenance of effective urine output vol-
ume, a better hyperparathyroidism control, and a good
nutritional status may have produced a positive effect on
erythropoiesis leading to better anemia correction with re-
duction of ERI [23-25]. Our findings are in keeping with
those of Di Iorio et al. who demonstrated that a poorer
response to EPO was related to secondary hyperparathyr-
oidism [23]. At baseline, in 50% of THD patients PTH
was >300 pg/ml with significantly higher serum phosphate
levels and a significantly lower use of calcimimetic drugs
compared to CDDP Group (Tables 3 and 4). During the
study, CDDP patients had no need for additional dialysis
sessions. In turn, an easy volumes balance with quite low
interdialytic weight gains, and prevention of high ultrafil-
tration rates and of intradialytic hypotension, contribute
to the protection of RRF during CDDP. Moreover, Fouque
et al. showed that dietary treatment produced a positive
effect in delaying the need of dialysis [26].
It is noteworthy that the hospitalization rate in CDDP
was much lower than in THD Group. In the latter, the
causes of admission were mainly vascular access complica-
tions and infection. In addition the overall 2 year-survival
rate of CDDP was similar to that of THD patients. In fact,
data from literature show that a conservative approach
may be not inferior to dialysis in elderly ESRD patients, in
terms of survival and/or quality of life [27-29].
Lastly, the CDDP treatment resulted in an approxi-
mate 50% savings on the cost of drugs and dialysis re-
sources, including a lower number of dialysis hours/
nursing and medical staff ( 66% less compared to thrice-
weekly hemodialysis) and comorbid incidence in terms
of days of hospitalization, as well as of indirect costs
such as transport of patients to and from the dialysisunit. When compared to THD, the CDDP group showed a
lower hospitalization rate, lower need for expensive drugs,
and by definition a 66% lowering of number of dialysis ses-
sions and related costs. CDDP patients may have the add-
itional cost of the protein-free products. As a whole,
CDDP seems to be a safe and effective exit strategy for
lowering the cost of ESRD population, even if it can occur
for a limited period of time and in selected ESRD patients.
Another advantage of CDDP is an improvement in pa-
tient’s acceptance and adaptation to renal replacement ther-
apy. The patient feels less sick and less machine-dependent,
resulting in an increased copying capacity (or psychological
adaptation). Patients moreover tended to adapt better to
low protein diets thanks to a more varied diet, as well as to
address concerns about “dialysis-day”, which was also the
day they were allowed to eat a “normal” diet.
The study has not had the opportunity to randomize
and this may be seen as a limitation, but randomization
was not feasible because one could not force patients to
choose one method rather than the other. Patients were
followed in pre-dialysis care: a multidisciplinary clinic
(doctors, nurses, dietitians and psychologists) was able to
provide the necessary education and choice of treatment
modalities. This study aimed to reproduce the real world
clinical practice where patient’s adherence is a crucial issue
for the success of any treatment, especially if dietary in na-
ture, where patients play an active role and must be in-
volved in the decision-making process. Patients who
entered the CDDP showed a lower residual renal function
but better control of phosphatemia, BUN, PTH levels and
higher albumin levels. This finding suggests that CDDP is
suitable for patients who still have a positive inclination
towards dietary manipulations. Moreover, together with a
preserved urine output volume, good compliance to diet-
ary prescriptions is mandatory and a pre-requisite for the
success and safety of CDDP. Now it could be necessary to
begin considering a tailored dialytic treatment and to
evaluate the greater power of RRF. The incremental choice
is considered a good option in peritoneal patients since
the 2000’s [30,31] thanks to RRF and it again underesti-
mates for twice-weekly HD patients [32,33]. Energy-
adequate low-protein regimens have a fundamental role in
controlling and maintaining a good metabolic status and
in reducing GFR loss [26,34].
Conclusions
This study shows that in selected ESRD patients, a CDDP
is able to protect the RRF, to maintain urine volume output,
to preserve a good nutritional status , to blunt the rapid β2
microglobulin increase, and to allow better control of
anemia and calcium-phosphate abnormalities. CDDP is also
associated with a lower rate of hospitalization and reduced
need of EPO and drugs used for the CKD-MBD treatment,
thus leading to a significant cost-saving. As a whole, our
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http://www.biomedcentral.com/1471-2369/15/172findings suggest that CDDP could be a beneficial choice
for selected collaborative patients who would otherwise
be referred to thrice-weekly hemodialysis. CCDP should
be considered as the first step of an incremental ap-
proach to hemodialysis treatment in motivated and se-
lected ESRD patients, or anywhere dialysis facilities and
resources are lacking.
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